Thursday, 23 January 2020

Roche's Tecentriq fails trial in form of urothelial cancer

Roche's immunotherapy Tecentriq failed a late-stage clinical trial in a form of urothelial cancer, the Swiss drugmaker said on Friday.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)